Does EVINACUMAB-DGNB Cause Hepatic steatosis? 7 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Hepatic steatosis have been filed in association with EVINACUMAB-DGNB. This represents 7.6% of all adverse event reports for EVINACUMAB-DGNB.
7
Reports of Hepatic steatosis with EVINACUMAB-DGNB
7.6%
of all EVINACUMAB-DGNB reports
0
Deaths
0
Hospitalizations
How Dangerous Is Hepatic steatosis From EVINACUMAB-DGNB?
Of the 7 reports.
Is Hepatic steatosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVINACUMAB-DGNB. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does EVINACUMAB-DGNB Cause?
Nausea (14)
Fatigue (12)
Pain (9)
Diarrhoea (6)
Dizziness (6)
Drug ineffective (6)
International normalised ratio increased (6)
Product dose omission issue (6)
Death (5)
Headache (5)
What Other Drugs Cause Hepatic steatosis?
METHOTREXATE (1,400)
ADALIMUMAB (1,058)
ETANERCEPT (620)
TOCILIZUMAB (476)
TOFACITINIB (405)
LEFLUNOMIDE (359)
HYDROXYCHLOROQUINE (358)
ABATACEPT (345)
METFORMIN (343)
INFLIXIMAB (325)